Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma

Yoshimasu, Tatsuya; Miyoshi, Shinichiro; Maebeya, Shinji; Suzuma, Takaomi; Bessho, Toshiya; Hirai, Ikuko; Tanino, Hirokazu; Arimoto, Junji; Naito, Yasuaki

doi:10.1002/(sici)1097-0142(19970415)79:8<1533::aid-cncr14>3.0.co;2-z

Cited by 20 publications

(18 citation statements)

References 17 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After a short term increase immediately after the intervention due to marker release from operatively damaged normal and tumor tissue, the decline depends on both biological marker half-life and residual tumor cells [3,37,38]. After curative tumor resection, the levels of CYFRA 21-1, TPA, and SCC -which have a half life of about 1.5 to 3 hoursare expected to decrease rapidly reaching the range of healthy persons within one to two days.…”

Section: Post-surgery Follow Up Carementioning

confidence: 99%

“…After curative tumor resection, the levels of CYFRA 21-1, TPA, and SCC -which have a half life of about 1.5 to 3 hoursare expected to decrease rapidly reaching the range of healthy persons within one to two days. CEA decrease occurs with some delay depending on the initial marker level and a longer half life of one to four days [3,5,24,31,37,38]. It has to be emphasized that renal or liver dysfunction may prolong the half life of tumor markers considerably [19,21,29].…”

Section: Post-surgery Follow Up Carementioning

confidence: 99%

“…It has to be emphasized that renal or liver dysfunction may prolong the half life of tumor markers considerably [19,21,29]. If those interfering conditions are rouled out, a slowed marker clearance and/or an elevated plateau is indicative for the presence of residual tumor cells and predict early the recurrence of disease [37].…”

Section: Post-surgery Follow Up Carementioning

confidence: 99%

See 2 more Smart Citations

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Barak

Holdenrieder

Nisman

et al. 2010

CBM

View full text Add to dashboard Cite

As the release and amount of circulating biomarkers show considerable variations between individuals, single value determinations are often difficult to be interpreted on their diagnostic or prognostic significance on the individual level. However, changes of the biomarker levels in a specific person during the disease course are quite informative for the estimation of the efficacy of therapy or the early detection of recurrent disease because they consider only intraindividual variations. If methods for marker determination are maintained, preanalytical and analytical standard prerequistits are respected, thresholds for each marker have to be defined which exceeds the normal, intraindividual biological variation. Then continuous biomarker increases may be indicative for disease activity in terms of inefficient therapy response or tumor recurrence while decreasing values often are associated with activity reduction of cancer disease. Here, we review the current knowledge on biomarker kinetics in patients with non-small cell lung cancer (NSCLC) and discuss the conditions and pitfalls of their relevance for the estimation efficacy of therapy and the early detection of recurrent disease. Further, we suggest a scenario to reveal the power of the defined biomarker use in future and to include those markers into the individual management of NSCLC patients.

show abstract

Section: Post-surgery Follow Up Carementioning

confidence: 99%

Section: Post-surgery Follow Up Carementioning

confidence: 99%

Section: Post-surgery Follow Up Carementioning

confidence: 99%

See 1 more Smart Citation

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Barak

Holdenrieder

Nisman

et al. 2010

CBM

View full text Add to dashboard Cite

show abstract

“…Other studies have also shown the prognostic value of squamous cell carcinoma (SCC) antigen (9–11), carcinoembryonic antigen (CEA) (11–13), carbohydrate antigen 125 (CA125) (11,14) and even neuron-specific enolase (NSE) (15) in non-small cell lung cancer. It has also been shown that the most effective way of evaluating prognosis is dynamically, by comparing pre- and post-therapy results (16,17). …”

Section: Introductionmentioning

confidence: 99%

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy

et al. 2014

View full text Add to dashboard Cite

Cisplatin/pemetrexed chemotherapy has been established as a standard treatment in lung adenocarcinoma. However, the response to the cisplatin/pemetrexed combination varies considerably among patients due to individual variations. Thus, novel biomarkers are required to aid the prediction of the response to the cisplatin/pemetrexed combination. We hypothesized that leptin expression may be a determinant for prognosis in lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Serum from consenting patients with lung adenocarcinoma were obtained for the measurement of leptin and associated tumor biomarkers. Leptin expression was measured by radioimmunoassay. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA15-3, CA125, CA72-4, cytokeratin 19 fragment (CYFRA21-1) and neuron-specific enolase (NSE) expression were determined by electrochemiluminescence immunoassays. Serum squamous cell carcinoma antigen levels were measured using a microparticle enzyme immunoassay. The associations between serum leptin and tumor biomarker expression were evaluated by Spearman’s correlation analysis. Serum CEA, CA19-9, CA15-3, CA125, CA72-4, CYFRA21-1 and NSE levels showed no obvious difference among patients. However, a trend towards an improved prognosis was observed in patients with lower serum leptin at diagnosis and an increase during cisplatin/pemetrexed chemotherapy. The results indicated that the serum leptin level has prognostic indications in patients with advanced lung adenocarcinoma during cisplatin/pemetrexed chemotherapy, which indicates that it may be a useful marker for the prognosis of cancer patients undergoing chemotherapy treatment.

show abstract

“…We previously reported that these two parameters provided information about the prognosis of patients after surgery. 11,12) High postoperative CEA level at the plateau, as well as large postoperative CEA production, indicate the presence of remaining CEA-producing cancer cells. These two parameters may thus be able to predict tumor recurrence.…”

mentioning

confidence: 99%

Time course of carcinoembryonic antigen after resection of lung cancer: A predictor of recurrence

et al. 2003

Self Cite

View full text Add to dashboard Cite

We investigated whether the early postoperative time course of carcinoembryonic antigen (CEA) level after resection of lung cancer could be used to predict patients' prognosis. Fifty-three lung cancer patients were included in this study. Postoperative serum CEA levels were calculated by means of non-linear least-squares fitting to the equation C(t) = = = =(C 0 -C p )exp(-kt) + + + +C p , where C(t) is postoperative CEA level, t is days after surgery, C 0 is CEA level at postoperative time 0, C p is CEA level at plateau, and k is the rate constant of elimination. Postoperative CEA production (P p ) was calculated as C p multiplied by k. C p and P p represent the numbers of residual tumor cells after surgery. More residual tumor cells yield higher values of C p and P p , and result in earlier recurrence.[Results] Kinetic parameters could be obtained for 30 patients whose preoperative CEA levels were sufficiently elevated. Cutoff levels as predictors for recurrence were 1.1 ng/ml for C p and 0.9 ng/ml/day for P p . The accuracy of prediction of recurrence using these cutoff levels was 79% with C p and 89% with P p . A very poor prognosis was observed for patients with P p over 0.9 ng/ ml/day. easurement of serum tumor marker levels in patients with malignancy is useful for monitoring responses to therapy. When serum tumor marker levels do not normalize after treatment, the existence of residual tumor cells is strongly suspected.1-6) After surgical resection of tumors, serum tumor marker levels decrease in accordance with their individual elimination kinetics to a certain plateau level, [6][7][8][9][10] which is determined by the amount of postoperative tumor marker-producing cells remaining. These remaining tumor marker-producing cells may consist in part of residual tumor cells when the plateau level is higher than the normal range.Serum carcinoembryonic antigen (CEA) levels in lung cancer patients exhibit monophasic elimination patterns after surgical resection of tumors.11) Evaluation of postoperative CEA timecourse changes by using non-linear least-squares analysis considering residual CEA-producing cells enables calculation of postoperative CEA level at plateau and postoperative CEA production. We previously reported that these two parameters provided information about the prognosis of patients after surgery.11, 12) High postoperative CEA level at the plateau, as well as large postoperative CEA production, indicate the presence of remaining CEA-producing cancer cells. These two parameters may thus be able to predict tumor recurrence.This study examined the diagnostic accuracy of the CEA time-course after surgery as a predictor of recurrence after resection of lung cancer. Patients and MethodsPatients. A total of 53 patients who underwent radical resection for primary lung cancer at our institute from February 1993 to June 1997, and from whom informed consent for blood sampling was obtained, were included in the study. The patients were 42 males and 11 females, ranging in age from 30 to 81 years (average 65±11...

show abstract

Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma

Abstract: Although PROD is more sensitive than PLAT, both parameters appear to be useful as prognostic tools for predicting early recurrence after resection of lung carcinoma. This is probably because they represent the number of residual tumor cells immediately after surgery.

Cited by 20 publications

References 17 publications

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy

Time course of carcinoembryonic antigen after resection of lung cancer: A predictor of recurrence

Contact Info

Product

Resources

About